Skip to main content
. 2019 Dec 14;394(10215):2173–2183. doi: 10.1016/S0140-6736(19)32519-X

Table 2.

Weighted baseline characteristics for cholesterol-related measures

Cholesterol-lowering medication LDL cholesterol (mmol/L) HDL cholesterol (mmol/L) Non-HDL cholesterol (mmol/L) Non-HDL cholesterol categories
<2·6 mmol/L 2·6 to <3·7 mmol/L 3·7 to <4·8 mmol/L 4·8 to <5·7 mmol/L ≥5·7 mmol/L
All (n=398 846) 12 311 (4·9%) 3·6 (2·9–4·3) 1·3 (1·1–1·6) 4·3 (3·5–5·2) 16 572 (5·1%) 85 811 (26·2%) 109 270 (33·3%) 67 099 (20·4%) 49 575 (15·1%)
Numbers available 247 733 (59·7%) 264 999 (60·1%) 328 517 (74·4%) 328 327 (74·3%) 328 327 (74·3%) 328 327 (74·3%) 328 327 (74·3%) 328 327 (74·3%) 328 327 (74·3%)
Derivation (n=199 415) 6081 (4·9%) 3·6 (2·9–4·3) 1·3 (1·1–1·6) 4·3 (3·5–5·2) 8194 (5·1%) 42 941 (26·2%) 54 771 (33·4%) 33 463 (20·3%) 24 804 (15·1%)
Numbers available 123 904 (60·3%) 132 424 (60·5%) 164 276 (75·0%) 164 173 (74·9%) 164 173 (74·9%) 164 173 (74·9%) 164 173 (74·9%) 164 173 (74·9%) 164 173 (74·9%)
Validation (n=199 431) 6230 (5·0%) 3·6 (2·9–4·3) 1·3 (1·1–1·6) 4·3 (3·5–5·2) 8378 (5·1%) 42 870 (26·2%) 54 499 (33·2%) 33 636 (20·4%) 24 771 (15·0%)
Numbers available 123 829 (59·0%) 132 575 (59·6%) 164 241 (73·8%) 164 154 (73·7%) 164 154 (73·7%) 164 154 (73·7%) 164 154 (73·7%) 164 154 (73·7%) 164 154 (73·7%)
p value 0·18 0·79 0·01 0·79 0·85 0·99 0·58 0·29 0·64

Data are n (%) for numbers available, median (IQR) for continuous variables, n (%) of participants or % (95% CI) for categorical variables. p values are given for the validation cohort versus the derivation cohort using weighted versions of the Mann-Whitney and χ2 test. Due to the presence of the Estonian case-cohort dataset, the summary estimates (% and median (IQR)) are weighted by the inverse of the inclusion probability for individuals in that cohort. The individuals from other cohorts are given weight 1 in the computation. Totals (n) are not weighted. From the Estonian data only, the sub-cohort is used in the table computations.